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ABSTRACT 
Objective: The aim of this study was the in vitro evaluation of naproxen sodium and acetaminophen from fixed-dose combination generic drugs 
based on the hydrodynamic environment generated by the flow-through cell method (USP Apparatus 4). 
Methods: Dissolution studies were carried out using a USP Apparatus 4 Sotax CE6 with 22.6 mm cells, laminar flow at 16 ml/min, and 0.1 M 
phosphate buffer pH 7.4 at 37.0±0.5 °C as dissolution medium. Both drugs were identified and quantified by a validated first-order derivative 
spectrophotometric method. Measurements were achieved at 243.26 and 297.0 nm for naproxen sodium and acetaminophen, respectively. 
Dissolution profiles of generic drugs were compared with similarity factor f2, t50%, t85%, t90%
Results: According to f
 values as well as model-dependent and independent 
methods. 
2 values, dissolution profiles of all generic drugs were considered dissimilar to the dissolution profiles of the reference 
product (f2<50). Significant differences in t50%, t85%, t90%
Conclusion: The flow-through cell method was adequate for the in vitro evaluation of fixed-dose combination generic drugs containing naproxen 
sodium and acetaminophen. It should be necessary to evaluate the in vivo performance of fixed-dose generic formulations that contain naproxen 
sodium and acetaminophen in order to assure bioequivalence. 
, mean dissolution time and dissolution efficiency values were found (*P<0.05). Dissolution 
data better adjusted to Makoid-Banakar and Weibull’s kinetic models. 
Keywords: Naproxen sodium, Acetaminophen, Flow-through cell method, Fixed-dose combination generic drugs, First-order derivative 
spectrophotometry. 
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INTRODUCTION 
Generic drug products are off-patent formulations that contain the 
same active ingredient in the same dose as the reference product, 
and are administered by the same route [1]. At the clinic, is desirable 
to achieve the same therapeutic effect when the reference product is 
replaced by a generic formulation. The best way to assure an 
adequate in vivo performance of a generic drug is to conduct a 
bioequivalence study in humans. However, sometimes in vitro 
dissolution studies might contribute to establishing the inter-
changeability of generic drugs [2]. 
From a public health point of view, the development of fixed-dose 
combination formulations has recently gained importance. These 
formulations are cheaper than the separate products [3]. During the 
development of fixed-dose formulations in vitro dissolution studies 
can be helpful in understanding the critical parameters that affect 
the in vivo performance of drugs [4]. 
In Mexico, the fixed 1:09 formulation of naproxen sodium and 
acetaminophen is marketed as an over-the-counter (OTC) product. 
Naproxen is a poorly soluble non-steroidal anti-inflammatory drug 
that is used for the treatment of rheumatoid disorders (arthritis and 
osteoarthritis), dysmenorrhea, and pain [5]. Acetaminophen shows 
adequate analgesic and antipyretic properties but weak anti-
inflammatory activity and it is used in the symptomatic management 
of moderate pain and fever [6]. Co-administration of naproxen 
sodium and acetaminophen is indicated for the treatment of 
symptomatic pain and fever [7]. Chemical structures of both drugs 
are presented in fig. 1. 
According to Biopharmaceutical Classification System, drugs are 
classified on the basis of their solubility and gastrointestinal 
permeability: Naproxen has been classified as a Class II drug [8] (low 
solubility/high permeability), and acetaminophen as a Class III drug 
[6] (high solubility/low permeability). In vitro dissolution studies 
might be used to predict in vivo performance for Class II drugs and 
an in vitro/in vivo correlation (IVIVC) can be expected. For certain 
drugs, international guidelines suggest the waiver of bioequivalence 
studies by in vitro dissolution studies; a bio-waiver monograph for 
acetaminophen tablets has been previously reported [6]. The 
pharmacopeial dissolution test for naproxen and acetaminophen 
tablets are separately described [9] but to date, no official 




Fig. 1: Chemical structure of naproxen sodium (N) and 
acetaminophen (A) 
 
A bioequivalence study for a fixed-dose combination formulation 
containing naproxen sodium and acetaminophen was previously 
published [7]. The study was carried out with healthy volunteers 
and 275/300 mg tablets. The test formulation was found to be 
bioequivalent to the corresponding reference product. On the other 
hand, an in vitro dissolution study of naproxen sodium and 
acetaminophen from different fixed-dose combination formulations 
was previously reported [11]. Dissolution profiles were carried out 
with the USP paddle apparatus at 75 rpm and 900 ml of 0.1 M 
phosphate buffer pH 7.4 as dissolution medium. Both drugs were 
quantified by a first-order derivative spectrophotometric method. 
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Using similarity factor f2 only two of five commercial formulations 
were considered similar to the reference product (f2 
An alternative to evaluate the in vitro drug release from oral dosage 
forms is the open flow-through cell method (USP Apparatus 4) [12-
14]. Its advantages over traditional closed rotating basket apparatus 
(USP Apparatus 1) and rotating paddle type (USP Apparatus 2) are 
widely demonstrated, especially in the dissolution of poorly soluble 
drugs [15-16]. IVIVC for these drugs has been established using the 
USP Apparatus 4 [17-18]. The method is more reliable, reproducible, 
and discriminative than others [19-20]. Therefore, it is important to 
investigate its utility on the assessment of naproxen sodium and 
acetaminophen dissolution profiles in fixed-dose combination 
formulations. 
>50). With 
model-independent comparisons significant differences in all 
generic formulations were found (*P <0.05). 
The objective of this study was to evaluate the in vitro release of 
naproxen sodium and acetaminophen from fixed-dose combination 
generic drugs based on the hydrodynamic environment generated 
by the flow-through cell method, USP Apparatus 4. 
MATERIALS AND METHODS 
Products and standard solutions 
Five Mexican naproxen sodium and acetaminophen tablets (coded as 
A, B, C, D and E) from fixed-dose combination generic drugs (275 mg 
of naproxen sodium/300 mg of acetaminophen) were used. 
Dissolution profiles of these products were compared to the 
dissolution profiles of Febrax® product (Siegfried Rhein, S. A. de C. 
V., Mexico). Mexican health regulatory agency (COFEPRIS) has 
established this product as the reference to be used in 
bioequivalence studies [21]. Phosphate salts were purchased from J. 
T. Baker-Mexico. Naproxen sodium and acetaminophen standards 
were purchased from Sigma-Aldrich Co. (St. Louis MO, USA). All 
samples were filtered through 0.45 µm nitrocellulose filters 
(Millipore®
Standard solutions of both drugs were separately prepared by serial 
dilutions of the stock solutions of naproxen sodium (0.1 mg/ml) and 
acetaminophen (1 mg/ml) in 0.1 M phosphate buffer pH 7.4 to 
achieve concentrations of 10–50 and 100–300 µg/ml, respectively. 
, Ireland). 
Content uniformity and assay 
Content uniformity and assay tests were performed with all fixed-
dose combination drugs, according to the procedures described in 
the USP [9]. 
Analytical method validation 
The analytical method was previously validated according to ICH 
guidelines [22]. The system linearity, accuracy, and precision were 
analyzed. 
Flow-through cell system 
Dissolution profiles of naproxen sodium and acetaminophen tablets 
were obtained with an automated flow-through cell method [23-25] 
(Sotax CE6, Sotax AG, Switzerland) with 22.6 mm cells (i.d.) and a 
piston pump (Sotax CY7−50, Sotax AG, Switzerland). In all 
experiments, laminar flow (with a bed of 6 g of glass beads) at 
37.0±0.5 °C was used. The deaerated 0.1 M phosphate buffer pH 7.4 
at a flow rate of 16 ml/min was used as dissolution medium. 
Dissolution samples were withdrawn at 10, 20, 30, 45, and 60 min. 
In all cases, twelve tablets were used. 
First-order derivative spectrophotometric analysis 
Simultaneous determination of naproxen sodium and 
acetaminophen was carried out with a first-order derivative 
spectroscopic method [11]. A double beam UV/Vis spectro-
photometer (Perkin Elmer Lambda 35, Waltham MA, USA) with 0.1 
cm quartz cells was utilized. The operating conditions were the first-
derivative mode with scan speed 240 nm/min, slit width 2.0 nm, and 
sampling interval 1.0 nm. The amounts of naproxen sodium and 
acetaminophen in each sample were determined at 243.26 and 
297.0 nm respectively, with reference to standard calibration curves. 
Data analysis 
Dissolution profiles of naproxen sodium and acetaminophen of 
fixed-dose combination generic drugs were compared with 
dissolution profiles of the reference product using the similarity 
factor f2. An f2 value between 50 and 100 suggests that the two 
dissolution profiles are similar. Furthermore, dissolution data of 
each formulation were used to calculate model-independent 
parameters: time to dissolved 50, 85, and 90% of the dose (t50%, 
t85%, t90%), mean dissolution time (MDT) and dissolution efficiency 
(DE). The values of these parameters were compared with the reference 
product values by ANOVA followed by Dunnett’s or Dunnett’s T3 
multiple comparisons test as appropriate. Data analysis was carried out 
using SPSS software (Version 17.0). Differences were considered 
significant if *P<0.05. Additionally, in order to evaluate the release 
kinetics of naproxen sodium and acetaminophen from the generic drugs, 
dissolution data were fitted to different kinetic models: First-order, 
Higuchi, Hixson-Crowell, Makoid-Banakar, and Weibull. The model with 
a highest determination coefficient (R2adjusted
RESULTS AND DISCUSSION 
) and minimum Akaike 
Information Criterion (AIC) was chosen as the best fit [26]. Data analysis 
was carried out using Excel add-in DD Solver program [27]. 
Pharmacopeial tests 
All fixed-dose combination generic drugs met the content uniformity 
and assay tests specified in the USP. The percentages of naproxen 
sodium and acetaminophen on the content uniformity test ranged 
from 85 to 115%, and the assay test was between 90 and 110% [11]. 
Analytical method validation 
The analytical method validation was previously reported [11]. All 
fixed-dose combination generic drugs met standard validation criteria. 
Dissolution profiles 
Naproxen sodium and acetaminophen dissolution profiles obtained with 
the flow-through cell method, USP Apparatus 4, are shown in fig. 2. 
 
Fig. 2: Dissolution profiles of naproxen sodium and 
acetaminophen from reference (R) and fixed-dose combination 
formulations (A-E) using the flow-through cell method. Mean, 
n=12. Error bars were omitted for clarity 
Results showed slower dissolution rates than those reported with 
the use of USP paddle method [11]. This behavior can be explained 
by the hydrodynamic conditions that characterize this dissolution 
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equipment that better reflects the natural environment of the 
gastrointestinal tract, causing different in vitro dissolution pattern 
[28]. In this study, flow rate of 16 ml/min was used because is one of 
the three flow rates (4, 8, and 16 ml/min) suggested by the 
American and European Pharmacopoeias [29]. Additionally, IVIVC 
using flow-through cell data at flow rates of 8, 16, and 32 ml/min has 
been previously discussed [30]. Similarity factor f2 for each fixed-
dose combination generic drugs are shown in fig. 3. By the results 
obtained (f2
t
<50) none of the dissolution profiles, of naproxen sodium 
or acetaminophen, of the generic formulations were considered 
similar to the dissolution profiles of the reference product. 
Model-independent comparisons 
50%, t85%, t90% values and model-independent parameters MDT and 
DE mean values±standard error medium (SEM) for the studied 
products are shown in table 1. Considering t50%, t85%, t90%
 
 values and 
model-independent parameters, significant differences in 
dissolution profiles of naproxen sodium and acetaminophen from all 
fixed-dose combination generic drugs were found (*P <0.05). 
Fig. 3: Similarity factor f2 of naproxen sodium (grey bars) and 
acetaminophen (white bars) from fixed-dose combination 
formulations (A-E). None dissolution profile was considered 
similar to the dissolution profile of the reference product (f2
 
<50).
Table 1: t50%, t85%, t90%
Code 
 values and model-independent parameters: mean dissolution time (MDT) and dissolution efficiency (DE) from 
fixed-dose combination generic formulations (A-E). mean±SEM, n=12. *P<0.05 
t50% t (min) 85% t (min) 90% MDT (min)  (min) DE (%) 
Naproxen sodium 
R 32.03±0.22 56.94±0.10 60.69±0.13 29.37±0.14 46.08±0.20 
A 8.50±0.23* 23.76±0.43* 27.73±0.44* 14.75±0.17* 81.85±0.39* 
B 13.23±0.20* 33.66±0.32* 38.36±0.32* 16.56±0.20* 72.09±0.32* 
C 16.60±0.17* 37.72±0.21* 41.96±0.21* 19.34±0.13* 67.83±0.23* 
D 19.04±0.27* 42.59±0.27* 47.24±0.24* 22.51±0.19* 83.77±1.05* 
E 12.64±0.37* 33.20±0.60* 38.14±0.63* 17.01±0.37* 85.45±1.95* 
Acetaminophen 
R 33.86±0.18 57.65±0.20 61.06±0.22 30.17±0.11 44.15±0.23 
A 6.14±0.07* 20.43±0.18* 25.06±0.21* 10.29±0.13* 83.35±0.17* 
B 13.97±0.14* 33.72±0.19* 37.98±0.18* 17.03±0.11* 72.12±0.20* 
C 17.05±0.24* 37.78±0.29* 41.82±0.27* 19.71±0.16* 67.62±0.34* 
D 17.45±0.26* 38.94±0.29* 43.16±0.26* 20.18±0.19* 84.35±0.98* 
E 13.17±0.55* 36.14±0.92* 42.02±0.97* 16.11±0.44* 77.98±2.62* 
 
Table 2: Criteria used for the selection of the best kinetic model 
Code First-order Higuchi Hixson-Crowell Makoid-Banakar Weibull 
R2 adjusted 
Naproxen sodium 
R 0.9210 0.8291 0.9598 0.9976 0.9853 
A 0.8853 0.8118 0.9207 0.9514 0.8170 
B 0.9128 0.8504 0.9617 0.9780 0.9945 
C 0.9092 0.8866 0.9636 0.9974 0.9967 
D 0.9482 0.9506 0.9864 0.9927 0.9955 
E 0.9330 0.8615 0.9703 0.9639 0.9837 
Acetaminophen 
R 0.9065 0.7941 0.9481 0.9987 0.9924 
A 0.9279 0.1390 0.9238 0.9204 0.9966 
B 0.8812 0.8405 0.9408 0.9801 0.9960 
C 0.8913 0.8681 0.9499 0.9988 0.9972 
D 0.9132 0.9137 0.9664 0.9704 0.9862 
E 0.9463 0.8400 0.9640 0.9693 0.9915 
AIC 
Naproxen sodium 
R 29.71 33.58 26.29 11.80 21.61 
A 29.22 31.54 27.20 25.08 31.96 
B 30.38 33.08 26.25 23.98 16.77 
C 31.46 32.56 26.74 10.61 12.96 
D 27.53 27.19 20.70 17.83 15.52 
E 28.28 31.96 24.02 25.11 20.0 
Acetaminophen 
R 30.93 34.89 27.92 4.67 18.69 
A 25.0 37.46 25.11 25.88 6.27 
B 32.75 34.24 29.24 24.10 15.10 
C 32.81 33.77 28.86 8.92 13.85 
D 30.87 30.82 26.06 25.99 22.11 
E 26.51 32.06 24.42 22.72 16.15 
Mean, n=12 
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Model-independent parameters MDT and DE have been proposed as 
adequate parameters for some IVIVC levels [31]. Level B represents 
a relationship between MDT and the mean residence time, both 
calculated by statistical moment’s theory, and Level C is established 
by the association of a dissolution time point (t50% , t90%, etc.) to one 
pharmacokinetic parameter such as area under the curve, Cmax, or 
Tmax
From the obtained results with fixed-dose combination generic drugs 
of naproxen sodium and acetaminophen, the flow-through cell method 
was more discriminative than the USP paddle apparatus [11]. 
. Some authors have taken the DE as a suitable parameter that 
expresses a global drug dissolution performance useful for 
comparison of dissolution profiles [32]. 
Model-dependent comparisons 
In order to describe the naproxen sodium and acetaminophen 
release kinetics from fixed-dose combination generic drugs, data 
were fitted to several kinetic models. The dissolution data of 
naproxen sodium obtained from R, A, and C formulations were best 
fitted to Makoid-Banakar’s function and for B, D, and E generic drugs 
by Weibull’s equation. Dissolution data of acetaminophen from R 
and C formulations better adjusted to Makoid-Banakar’s model 
while A, B, D, and E generic drugs adjusted to Weibull’s equation. 
Results are shown in table 2. 
Because some fixed-dose combination generic drugs adjusted to 
different kinetic model to the one presented by the reference 
product, comparison of dissolution profiles by model-dependent 
methods was not possible. To compare dissolution profiles by this 
approach, all formulations should be adjusted at the same kinetic 
model [26]. 
Results of the present study agree with those previously reported 
for naproxen sodium and acetaminophen in fixed-dose combination 
formulations using the USP paddle apparatus [11]. Naproxen sodium 
data from A and E products as well as acetaminophen from A, B, D, 
and E generic formulations better adjusted to Weibull’s model while 
acetaminophen from the reference product better adjusted to 
Makoid-Banakar’s kinetics. 
In vitro evaluation of fixed-dose combination generic drugs must be 
a continuous control in order to verify the biopharmaceutical quality 
of all marketed drug products. In addition, in vitro dissolution 
profiles evaluation of generic formulations represents a regulatory 
specification for bio-waivers. Efforts should be made to ensure that, 
as much as possible, the in vitro dissolution methods employed 
reflect the in vivo performance of the studied generic drugs [33]. 
CONCLUSION 
The flow-through cell method, USP Apparatus 4, was proved to be a 
more discriminative in vitro dissolution method for the evaluation of 
the release performance of naproxen sodium and acetaminophen 
from different fixed-dose combination generic drugs. 
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